Park Ha Biological Technology Prices Follow-On Public Offering at $0.112
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2026
0mins
Park Ha Biological Technology announced the pricing of a best-efforts follow-on public offering of 21,875,000 units at an offering price of $0.112 per Unit. Each Unit consists of one Class A ordinary share of the Company, par value $0.00002 per share and one warrant to purchase one Class A Ordinary Share. Each Warrant will have an exercise price of $0.112 per Class A Ordinary Share and will be exercisable beginning on the issuance date and ending on the one-year anniversary of the issuance date. The Company expects to receive aggregate gross proceeds of $2.45M from the offering, before deducting placement agent commissions and other estimated expenses payable by the Company, excluding the exercise of any Warrant offered. The offering is expected to close on or about January 28, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for the expansion of directly operated stores in China, and the specific allocation of net proceeds to each market will be based on market conditions. D. Boral Capital is acting as the Sole Placement Agent for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BYAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BYAH
About BYAH
Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Park Ha Biological Successfully Launches on Amazon North America
- Global Expansion Milestone: Park Ha Biological has successfully passed Amazon North America's stringent approval process, marking a critical milestone in its global expansion strategy and receiving recognition for its brand strength and product competitiveness.
- Market Access Advantage: As the world's leading cross-border e-commerce platform, Amazon's high entry standards enhance Park Ha's market reputation and lay a solid foundation for its brand-building efforts in the high-end consumer market.
- Strategic Transformation Completed: This launch signifies Park Ha's strategic evolution from a 'premium domestic brand' to an 'emerging international brand', fully unlocking key access channels to the global high-end consumer market.
- Future Development Plans: The company will leverage Amazon's global traffic and logistics advantages to precisely adjust its product portfolio, enhance international brand exposure, and strive to become a domestically influential brand with global reach, helping more high-quality Chinese brands succeed internationally.
See More
Park Ha Biological Partners with Amazon for North American Market Expansion
- Market Entry Preparation: Park Ha Biological has initiated cooperation with Amazon North America, launching full-scale preparations for entry into the personal care market, including store qualification and brand registration, which is expected to accelerate its online commercialization and enhance brand presence in North America.
- Compliance Framework Establishment: The company is proactively establishing a compliance framework tailored to the North American market, ensuring a smooth market entry while meeting stringent regulatory requirements, thereby mitigating potential barriers and reinforcing the brand's commitment to quality and transparency.
- Significant Market Potential: The North American market boasts approximately 310 million active Amazon buyers, with 82% residing in the U.S., representing the world's largest and most mature personal care market, and the company's strategic positioning is set to enhance international brand equity.
- New Paradigm for Brand Internationalization: By entering the Amazon platform, Park Ha Biological is poised to unlock entirely new revenue channels, significantly broadening growth opportunities, accelerating global brand recognition, and establishing a new paradigm for brand internationalization.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Aditxt, Inc. (ADTX) surged 225% to $0.014 in pre-market trading, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 40% to $1.68, while Spero Therapeutics, Inc. (SPRO) increased by 10% to $4.37, reflecting an overall positive sentiment in the biotech sector that could drive industry investment momentum.
- Pre-Market Losers: Elicio Therapeutics, Inc. (ELTX) fell 20% to $3.78, and Profusa, Inc. (PFSA) dropped 26% to $0.19, highlighting market concerns over certain companies, which may lead investors to reassess risks.
- Market Volatility Factors: The fluctuations in pre-market trading are primarily driven by U.S. patent protections, FDA approvals, manufacturing deals, and trial goal misses, showcasing the complexities and potential risks within the biotech industry.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Gelteq Limited (GELS) surged 46% to $1.43 in pre-market trading, indicating strong market reaction to its clinical trial progress, which may attract further investor interest in its future performance.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 20% to $1.77, while Upexi, Inc. (UPXI) increased by 10% to $0.99, reflecting an overall positive sentiment in the biotech sector that could bolster market confidence in related companies.
- Pre-Market Declines: Elicio Therapeutics, Inc. (ELTX) plummeted 62% to $5.79 in pre-market trading, showcasing market disappointment over its clinical trial results, which may lead investors to reassess its future outlook.
- Other Declining Stocks: 20/20 Biolabs, Inc. (AIDX) fell 18% to $0.79, highlighting the market's sensitivity to risks associated with biotech companies, potentially impacting overall investment sentiment in the industry.
See More
Park Ha Biological Technology Co. Announces Direct Offering of Securities
- Offering Size: Park Ha Biological Technology Co. has entered into a securities purchase agreement to sell up to 1,133,332 Class A ordinary shares and 200,000 pre-funded warrants, with expected gross proceeds of approximately $2 million, indicating the company's active engagement in capital markets.
- Use of Proceeds: The net proceeds from this offering will be utilized for general corporate and working capital purposes, reflecting the company's strategic intent to expand operations and enhance market competitiveness.
- Closing Timeline: The offering is expected to close around June 15, 2026, subject to customary closing conditions, demonstrating the company's timing acumen and commitment to investors.
- Registration Statement: The securities are being offered under an effective F-3 registration statement, ensuring compliance and providing transparent disclosures to investors, thereby bolstering market confidence.
See More
Park Ha Biological Technology Secures $2 Million in Direct Offering
- Financing Agreement: Park Ha Biological Technology has entered into a securities purchase agreement with several investors to sell up to 1,133,332 Class A ordinary shares and 200,000 pre-funded warrants, expecting gross proceeds of approximately $2 million, reflecting strong market confidence in its business.
- Clear Use of Funds: The proceeds from this offering will be utilized for general corporate and working capital purposes, indicating the company's strategic intent to expand its skincare brand 'Park Ha' and related services, aiming to enhance its competitive position in the market.
- Transparent Issuance Details: The securities are being offered under an effective F-3 registration statement, with the offering expected to close on June 15, 2026, complying with relevant U.S. securities laws, which enhances investor trust.
- Defined Market Positioning: Since its establishment in 2016, Park Ha has opened five directly operated stores and 22 franchisees in China, committed to providing cost-effective skincare solutions, thereby solidifying its position in the rapidly growing skincare market.
See More
Park Ha Biological Successfully Launches on Amazon North America
- Global Expansion Milestone: Park Ha Biological has successfully passed Amazon North America's stringent approval process, marking a critical milestone in its global expansion strategy and receiving recognition for its brand strength and product competitiveness.
- Market Access Advantage: As the world's leading cross-border e-commerce platform, Amazon's high entry standards enhance Park Ha's market reputation and lay a solid foundation for its brand-building efforts in the high-end consumer market.
- Strategic Transformation Completed: This launch signifies Park Ha's strategic evolution from a 'premium domestic brand' to an 'emerging international brand', fully unlocking key access channels to the global high-end consumer market.
- Future Development Plans: The company will leverage Amazon's global traffic and logistics advantages to precisely adjust its product portfolio, enhance international brand exposure, and strive to become a domestically influential brand with global reach, helping more high-quality Chinese brands succeed internationally.
See More
Park Ha Biological Partners with Amazon for North American Market Expansion
- Market Entry Preparation: Park Ha Biological has initiated cooperation with Amazon North America, launching full-scale preparations for entry into the personal care market, including store qualification and brand registration, which is expected to accelerate its online commercialization and enhance brand presence in North America.
- Compliance Framework Establishment: The company is proactively establishing a compliance framework tailored to the North American market, ensuring a smooth market entry while meeting stringent regulatory requirements, thereby mitigating potential barriers and reinforcing the brand's commitment to quality and transparency.
- Significant Market Potential: The North American market boasts approximately 310 million active Amazon buyers, with 82% residing in the U.S., representing the world's largest and most mature personal care market, and the company's strategic positioning is set to enhance international brand equity.
- New Paradigm for Brand Internationalization: By entering the Amazon platform, Park Ha Biological is poised to unlock entirely new revenue channels, significantly broadening growth opportunities, accelerating global brand recognition, and establishing a new paradigm for brand internationalization.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Aditxt, Inc. (ADTX) surged 225% to $0.014 in pre-market trading, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 40% to $1.68, while Spero Therapeutics, Inc. (SPRO) increased by 10% to $4.37, reflecting an overall positive sentiment in the biotech sector that could drive industry investment momentum.
- Pre-Market Losers: Elicio Therapeutics, Inc. (ELTX) fell 20% to $3.78, and Profusa, Inc. (PFSA) dropped 26% to $0.19, highlighting market concerns over certain companies, which may lead investors to reassess risks.
- Market Volatility Factors: The fluctuations in pre-market trading are primarily driven by U.S. patent protections, FDA approvals, manufacturing deals, and trial goal misses, showcasing the complexities and potential risks within the biotech industry.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Gelteq Limited (GELS) surged 46% to $1.43 in pre-market trading, indicating strong market reaction to its clinical trial progress, which may attract further investor interest in its future performance.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 20% to $1.77, while Upexi, Inc. (UPXI) increased by 10% to $0.99, reflecting an overall positive sentiment in the biotech sector that could bolster market confidence in related companies.
- Pre-Market Declines: Elicio Therapeutics, Inc. (ELTX) plummeted 62% to $5.79 in pre-market trading, showcasing market disappointment over its clinical trial results, which may lead investors to reassess its future outlook.
- Other Declining Stocks: 20/20 Biolabs, Inc. (AIDX) fell 18% to $0.79, highlighting the market's sensitivity to risks associated with biotech companies, potentially impacting overall investment sentiment in the industry.
See More
Park Ha Biological Technology Co. Announces Direct Offering of Securities
- Offering Size: Park Ha Biological Technology Co. has entered into a securities purchase agreement to sell up to 1,133,332 Class A ordinary shares and 200,000 pre-funded warrants, with expected gross proceeds of approximately $2 million, indicating the company's active engagement in capital markets.
- Use of Proceeds: The net proceeds from this offering will be utilized for general corporate and working capital purposes, reflecting the company's strategic intent to expand operations and enhance market competitiveness.
- Closing Timeline: The offering is expected to close around June 15, 2026, subject to customary closing conditions, demonstrating the company's timing acumen and commitment to investors.
- Registration Statement: The securities are being offered under an effective F-3 registration statement, ensuring compliance and providing transparent disclosures to investors, thereby bolstering market confidence.
See More
Park Ha Biological Technology Secures $2 Million in Direct Offering
- Financing Agreement: Park Ha Biological Technology has entered into a securities purchase agreement with several investors to sell up to 1,133,332 Class A ordinary shares and 200,000 pre-funded warrants, expecting gross proceeds of approximately $2 million, reflecting strong market confidence in its business.
- Clear Use of Funds: The proceeds from this offering will be utilized for general corporate and working capital purposes, indicating the company's strategic intent to expand its skincare brand 'Park Ha' and related services, aiming to enhance its competitive position in the market.
- Transparent Issuance Details: The securities are being offered under an effective F-3 registration statement, with the offering expected to close on June 15, 2026, complying with relevant U.S. securities laws, which enhances investor trust.
- Defined Market Positioning: Since its establishment in 2016, Park Ha has opened five directly operated stores and 22 franchisees in China, committed to providing cost-effective skincare solutions, thereby solidifying its position in the rapidly growing skincare market.
See More
